NTLA Fundamental Analysis - INTELLIA THERAPEUTICS INC

Name: INTELLIA THERAPEUTICS INC (NTLA) Stock
Brand: INTELLIA THERAPEUTICS INC
Rating: 3.5 (3 reviews)

Fundamental Rating

Overall NTLA gets a fundamental rating of 3 out of 10. We evaluated NTLA against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTLA as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, NTLA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

NTLA had negative earnings in the past year.

NTLA had a negative operating cash flow in the past year.

NTLA had negative earnings in each of the past 5 years.

In the past 5 years NTLA always reported negative operating cash flow.

1.2 Ratios

NTLA has a Return On Assets (-48.18%) which is comparable to the rest of the industry.

Looking at the Return On Equity, with a value of -59.57%, NTLA is in the better half of the industry, outperforming 61.77% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-48.18%
ROE	-59.57%
ROIC	N/A

ROA(3y)-37.25%

ROA(5y)-30.46%

ROE(3y)-47.91%

ROE(5y)-38.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NTLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NTLA has more shares outstanding

The number of shares outstanding for NTLA has been increased compared to 5 years ago.

NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

NTLA has an Altman-Z score of -1.08. This is a bad value and indicates that NTLA is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -1.08, NTLA perfoms like the industry average, outperforming 55.18% of the companies in the same industry.

There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.08

ROIC/WACCN/A

WACC8.77%

2.3 Liquidity

NTLA has a Current Ratio of 6.21. This indicates that NTLA is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 6.21, NTLA is doing good in the industry, outperforming 65.91% of the companies in the same industry.

NTLA has a Quick Ratio of 6.21. This indicates that NTLA is financially healthy and has no problem in meeting its short term obligations.

NTLA's Quick ratio of 6.21 is fine compared to the rest of the industry. NTLA outperforms 66.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.21
Quick Ratio	6.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NTLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.51%, which is quite impressive.

Looking at the last year, NTLA shows a very negative growth in Revenue. The Revenue has decreased by -29.22% in the last year.

The Revenue has been growing slightly by 6.07% on average over the past years.

EPS 1Y (TTM)21.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%31.34%

Revenue 1Y (TTM)-29.22%

Revenue growth 3Y20.53%

Revenue growth 5Y6.07%

Sales Q2Q%51.27%

3.2 Future

Based on estimates for the next years, NTLA will show a very strong growth in Earnings Per Share. The EPS will grow by 30.32% on average per year.

The Revenue is expected to grow by 106.97% on average over the next years. This is a very strong growth

EPS Next Y19.85%

EPS Next 2Y11.12%

EPS Next 3Y10.19%

EPS Next 5Y30.32%

Revenue Next Year14.89%

Revenue Next 2Y-2.32%

Revenue Next 3Y14.76%

Revenue Next 5Y106.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NTLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NTLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.12%

EPS Next 3Y10.19%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NTLA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (11/11/2025, 8:00:02 PM)

Premarket: 10.29 +0.11 (+1.08%)

10.18

+0.45 (+4.62%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2025-11-06/amc

Earnings (Next)02-25 2026-02-25/amc

Inst Owners88.25%

Inst Owner Change-2.54%

Ins Owners1.43%

Ins Owner Change0.78%

Market Cap1.09B

Revenue(TTM)57.53M

Net Income(TTM)-445.81M

Analysts76.77

Price Target33.78 (231.83%)

Short Float %30.3%

Short Ratio5.3

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)7.79%

Min EPS beat(2)5.61%

Max EPS beat(2)9.97%

EPS beat(4)4

Avg EPS beat(4)9.46%

Min EPS beat(4)5.61%

Max EPS beat(4)15.91%

EPS beat(8)7

Avg EPS beat(8)5.45%

EPS beat(12)10

Avg EPS beat(12)5.75%

EPS beat(16)11

Avg EPS beat(16)-1.99%

Revenue beat(2)1

Avg Revenue beat(2)1.92%

Min Revenue beat(2)-11.02%

Max Revenue beat(2)14.86%

Revenue beat(4)3

Avg Revenue beat(4)22.26%

Min Revenue beat(4)-11.02%

Max Revenue beat(4)47.93%

Revenue beat(8)5

Avg Revenue beat(8)8.79%

Revenue beat(12)8

Avg Revenue beat(12)8.08%

Revenue beat(16)12

Avg Revenue beat(16)14.96%

PT rev (1m)-6.91%

PT rev (3m)-7.57%

EPS NQ rev (1m)-0.8%

EPS NQ rev (3m)-0.92%

EPS NY rev (1m)-0.33%

EPS NY rev (3m)1.13%

Revenue NQ rev (1m)2.17%

Revenue NQ rev (3m)22.4%

Revenue NY rev (1m)-0.64%

Revenue NY rev (3m)8.86%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	19
P/FCF	N/A
P/OCF	N/A
P/B	1.46
P/tB	1.46
EV/EBITDA	N/A

EPS(TTM)-4.27

EYN/A

EPS(NY)-4.02

Fwd EYN/A

FCF(TTM)-3.84

FCFYN/A

OCF(TTM)-3.83

OCFYN/A

SpS0.54

BVpS6.97

TBVpS6.97

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.18%
ROE	-59.57%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-37.25%

ROA(5y)-30.46%

ROE(3y)-47.91%

ROE(5y)-38.99%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	15.91%
Cap/Sales	3.45%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.21
Quick Ratio	6.21
Altman-Z	-1.08

F-Score4

WACC8.77%

ROIC/WACCN/A

Cap/Depr(3y)130.37%

Cap/Depr(5y)126.64%

Cap/Sales(3y)24.85%

Cap/Sales(5y)23.87%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)21.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%31.34%

EPS Next Y19.85%

EPS Next 2Y11.12%

EPS Next 3Y10.19%

EPS Next 5Y30.32%

Revenue 1Y (TTM)-29.22%

Revenue growth 3Y20.53%

Revenue growth 5Y6.07%

Sales Q2Q%51.27%

Revenue Next Year14.89%

Revenue Next 2Y-2.32%

Revenue Next 3Y14.76%

Revenue Next 5Y106.97%

EBIT growth 1Y47.57%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year16.9%

EBIT Next 3Y7.46%

EBIT Next 5Y8.88%

FCF growth 1Y-1.31%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-5.05%

OCF growth 3YN/A

OCF growth 5YN/A

INTELLIA THERAPEUTICS INC / NTLA FAQ

What is the ChartMill fundamental rating of INTELLIA THERAPEUTICS INC (NTLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NTLA.

What is the valuation status for NTLA stock?

ChartMill assigns a valuation rating of 0 / 10 to INTELLIA THERAPEUTICS INC (NTLA). This can be considered as Overvalued.

Can you provide the profitability details for INTELLIA THERAPEUTICS INC?

INTELLIA THERAPEUTICS INC (NTLA) has a profitability rating of 1 / 10.

Can you provide the expected EPS growth for NTLA stock?

The Earnings per Share (EPS) of INTELLIA THERAPEUTICS INC (NTLA) is expected to grow by 19.85% in the next year.

INTELLIA THERAPEUTICS INC (NTLA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INTELLIA THERAPEUTICS INC / NTLA FAQ

What is the ChartMill fundamental rating of INTELLIA THERAPEUTICS INC (NTLA) stock?

What is the valuation status for NTLA stock?

Can you provide the profitability details for INTELLIA THERAPEUTICS INC?

Can you provide the expected EPS growth for NTLA stock?